Shots:
- The FDA has approved Partner Therapeutics‘ Bizengri (zenocutuzumab-zbco) under CNPV, for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion who progressed on or after prior systemic therapy
- Approval was supported by eNRGy study assessing Bizengri in pts with NRG1 fusion-positive advanced solid tumors, incl. cholangiocarcinoma (n=22, where 19 were evaluable)
- Trial showed an ORR of 36.8% with a DoR range of 2.8 to 12.9mos. Additionally, Bizengri is included in the NCCN Guidelines for NSCLC, pancreatic adenocarcinoma, & cholangiocarcinoma
Ref: PRnewswire | Image: Partner | Press Release
Related News: Partner Therapeutics Reports P-II (eNRGy) Post-Hoc Results on Zenocutuzumab for NRG1+ NSCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
